OncoMed

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Private equity, CDK2, Patient, Foresite Capital, Eli Lilly and Company, New Enterprise Associates, Therapy, OrbiMed, NEA, OncoMed, Pharmaceutical industry

(“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.

Key Points: 
  • (“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.
  • The total capital raised since the company’s founding in August 2022 is $347 million.
  • In conjunction with the announcement, Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments, will join the Avenzo Board of Directors.
  • “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients,” said Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo.

Bioluminescence Ventures Reveals Partners and Investment Management Team

Retrieved on: 
Friday, January 5, 2024
Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Hospitals, Genetics, Science, Clinical Trials, Cardiology, Medical Supplies, Biology, Moores Cancer Center, Bank, Partner, OncoMed, Amgen, IND, Drug development, Biomedical engineering, Presidency College, Antibody, CFOS, CRA International, Spacecraft, Regenerative medicine, UC, Bank of America, Biomedical sciences, SVB Securities, Associate, BLV, University, University of California, Berkeley, Initial public offering, Venture, BMS, Electrical engineering, Genentech, UBS, Patient, Cell biology, Therapy, Economics, Biological engineering, Personalized medicine

Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.

Key Points: 
  • Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today revealed its initial team of Partners, whose collective experience and expertise spans preclinical research, translational science, clinical development, medical affairs, regulatory, commercial strategy, business development, and strategic investment banking functions across therapeutic areas.
  • Every day, I feel honored and lucky to be working with such talented, mission-driven, and caring people.”
    Chloe Kim, Ph.D. joined Bioluminescence Ventures as a Partner in 2022.
  • Negin Mokhtari, Ph.D. joined Bioluminescence Ventures as a Partner in 2023 and brings a blend of scientific expertise, operational experience, and investment skills to the firm.
  • Prior to joining Bioluminescence Ventures, Dr. Mokhtari was part of the investment team at Genoa Ventures, focusing on the convergence of biology and technology, and serving on the board of multiple companies.

OmniAb Announces the Passing of Director Sunil Patel

Retrieved on: 
Monday, August 7, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, ZymoGenetics, University, OncoMed, Berkeley, Marketing, Sunil, McKinsey & Company, Chemistry, Investment, Gilead Sciences, University of Washington Department of Bioengineering, Pleasure, Chairperson, Connetable (Gatchina), Ligand Pharmaceuticals, Management

OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week.
  • The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil’s many contributions to OmniAb.
  • “It is with profound sadness that we announce Sunil’s passing,” said John Higgins, OmniAb Board Chair.
  • “Sunil was a highly-valued and engaged member of the OmniAb Board of Directors and played an important role driving our investments and strategy.

Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
Molecular biology, Euronext Growth, Therapy, OncoMed, File, Doctor of Philosophy, TIL, Biotechnology, Gene editing, Research, Cellectis, Iovance Biotherapeutics, Harvard Medical School, CAR, Sheree Toth, IND, Pharmaceutical industry

“We are very excited to welcome Dr. Chartier as a director of Cellectis’ Board of Directors.

Key Points: 
  • “We are very excited to welcome Dr. Chartier as a director of Cellectis’ Board of Directors.
  • I am keen to lend my insights to the Cellectis’ Board of Directors to serve a patient population with severe unmet medical needs, where a successful allogeneic CAR T-cell product candidate could be a major breakthrough,” said Cécile Chartier, Ph.D., Cellectis newest Board member.
  • Cécile Chartier currently serves as Chief Scientific Officer at NextVivo, Inc.
  • She also worked at Shering (US Berlex) and Transgene (France), where she focused on gene therapy.

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

Retrieved on: 
Wednesday, June 28, 2023
Acumen, ABOS, LLP, University, OncoMed, Doctor of Philosophy, AbbVie, Stanford University, Epix Pharmaceuticals, ABBV, CSC, Cancer, Record, ASX, Babson College, PwC, IMU, Takeda Oncology, Proteostasis, Kineta, Molecular biology, Patient, CFO, Council, Therapy, Research and Development Council of New Jersey, NYSE, Biology, Pharmaceutical industry, Chimera, Biochemistry, Research

Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee.

Key Points: 
  • Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee.
  • Ms. Drapkin served as a member of Yumanity Therapeutics, Inc.’s board of directors since the completion of the merger of Proteostasis Therapeutics, Inc. and Yumanity, Inc. and previously served on the board of directors of Proteostasis.
  • Scott Dylla, Ph.D. is currently an entrepreneur, investor and advisor of early-stage biotech companies.
  • Dr. Dylla currently serves as the chairman of the board of Chimera Bioengineering and as a board member of 3D Bio Holdings LLC.

Sofinnova Investments Appoints Dr. Jakob Dupont as Executive Partner

Retrieved on: 
Tuesday, May 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Other Health, Memorial Sloan Kettering Cancer Center, GYN, Therapy, Senior, Investment, OncoMed, Stanford University, Vassar College, Clinical trial, Breast, Panasonic Executive Partner, Inflammation, Antibody, Assistant, Oncology, Philosophy, Patient, University, Internal medicine, Pleasure, MSK, IND, Joan, ADC, Hospital, R, Cornell University, Pharmaceutical industry, New York University

Sofinnova Investments , a healthcare investment firm, announced today the appointment of Jakob Dupont, M.D., to the investment team as an Executive Partner.

Key Points: 
  • Sofinnova Investments , a healthcare investment firm, announced today the appointment of Jakob Dupont, M.D., to the investment team as an Executive Partner.
  • Dr. Dupont brings more than two decades of experience in the field of oncology and other therapeutic areas, in developing therapies and programs dedicated to addressing high unmet medical needs.
  • Through his industry career he has contributed to 12 regulatory approvals and 13 successful IND filings.
  • “We’ve had the pleasure of knowing Jakob for a number of years, he has had a broad impact across the healthcare landscape, and we are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments.

Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors

Retrieved on: 
Thursday, March 30, 2023
Health, Diabetes, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Gaucher's disease, Genzyme, OncoMed, Chronic lymphocytic leukemia, MBA, Providence College, Strategic planning, Type 2, Patient, Hyperphosphatemia, Fabry disease, Therapy, Suffolk University, Imiglucerase, Sevelamer, Pharmaceutical industry, Management

Glyscend Therapeutics , a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Michael Wyzga to its Board of Directors.

Key Points: 
  • Glyscend Therapeutics , a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Michael Wyzga to its Board of Directors.
  • Mr. Wyzga brings over two decades of deep experience leading and advising life sciences companies to the Glyscend Board.
  • “We are thrilled to welcome Mike, a distinguished biotech industry expert, to the Glyscend team,” said Ashish Nimgaonkar, M.D., President and CEO of Glyscend.
  • I, along with the rest of the Board, look forward to his partnership.”
    Mr. Wyzga added, “I’m pleased to join the Glyscend Board of Directors during this exciting time for the company.

Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, December 13, 2022
Prostate, Master's degree, Universiade, Protein, Drug discovery, Neoplasm, Breast, SAN, Mayo Clinic, FDA, RAS, Cancer, General of the branch, Chicago (franchise), Columbia University, Doctor of Philosophy, Bevacizumab, Genentech, MD, Internal medicine, Drug development, Lung, SHG, Growth, Faculdade de Medicina da Universidade Federal de Minas Gerais, Business administration, Research, Mutation, Therapy, University of California, Berkeley, OncoMed, Senior, University, Clinical professor, Patient, KRAS, Pharmaceutical industry, Cabozantinib, Quanta, Exelixis

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced the appointment of Dr. Leonardo Faoro as Chief Medical Officer. Dr. Faoro brings more than 13 years of global clinical and regulatory experience advancing oncology medicines from early development stages through to approval, most recently serving as Senior Vice President and Early Clinical Development Lead at Exelixis, where he provided strategic leadership to expand the company's early clinical oncology pipeline and advance development candidates into the clinic.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced the appointment of Dr. Leonardo Faoro as Chief Medical Officer.
  • “We have made tremendous progress in advancing our novel RAS-targeted discovery programs with a unique focus on disrupting the active RAS signaling complex,” said Perry Nisen, MD, PhD, Chief Executive Officer of Quanta Therapeutics.
  • Quanta Therapeutics aims to advance two differentiated, next-generation RAS programs that address the resistance paradigms of targeted therapy in oncology.
  • Quanta Therapeutics is a private biopharmaceutical company focused on the most prevalent and elusive target in oncology—RAS.

Sensei Biotherapeutics Provides Update on Strategic Priorities

Retrieved on: 
Thursday, December 8, 2022
Max Planck Institute of Biochemistry, CD39, Investigational New Drug, Concluding observations on the second periodic report of the Holy See, Ludwig Maximilian University of Munich, Neoplasm, Max Planck Society, Tumor microenvironment, Amgen, Biochemistry, Chemistry, Daiichi Sankyo, Max Planck Institute of Neurobiology, FDA, Safety, Cancer, VISTA, Doctor of Philosophy, Schmidt Science Fellows, Workforce, Research, IND, Risk, OncoMed, ...Continued, Patient, Therapy, Vaccine, Pharmaceutical industry, Management, Sensei

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- eSensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced a streamlining and realignment of resources to support its key indications and programs, including its lead antibody, SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA, as well as its other TMAb™ (Tumor Microenvironment Activated biologics) platform programs.

Key Points: 
  • Sensei plans to relocate any ongoing work at its Boston research site to its Rockville, Maryland site.
  • “Our Board of Directors and management team remain focused on ensuring that Sensei is well positioned to execute on our near-term clinical and preclinical milestones.
  • Prior to joining Sensei in 2019, Dr. van der Horst worked at Zenith Epigenetics Ltd., Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and U3 Pharma GmbH (now Daiichi-Sankyo).
  • Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.

Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors

Retrieved on: 
Tuesday, November 8, 2022
Biotechnology, Pharmaceutical, Health, Oncology, National, LILRB4, LAIR1, LILRB2, White blood cell, Industry, Onyx Pharmaceuticals, Case Western Reserve University, Patient, Lymphatic system, Doctor of Philosophy, ILT4, GSK, NCI, Board, Leukemia & Lymphoma Society, Cancer, Immunotherapy, California Institute for Quantitative Biosciences, Chronic myelomonocytic leukemia, Regenerative medicine, University of California, Davis, UCSF, California Institute for Regenerative Medicine, Drug development, University, CIRM, National Cancer Institute, NIH, Board of directors, University of California, San Francisco, OncoMed, Leadership, Genentech, Medicine, Amgen, Record, Leukemia, Biology, Acute myeloid leukemia, BeiGene, LLS, Research, Therapy, Tumor microenvironment, AML, CMML, ILT3, Regeneron Pharmaceuticals, Cytokine, Vaccine, Pharmaceutical industry

"Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board.

Key Points: 
  • "Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board.
  • Immune-Oncs pioneering role in developing myeloid checkpoint inhibitors as next generation immunotherapies has impressed me, said Dr. Gurney.
  • Austin Gurney, Ph.D. is a biotech industry veteran with over two decades of experience in the discovery and development of novel therapeutics.
  • Immune-Oncs focused platform approach has led to the development of several promising therapeutics across various stages of development.